Aurinia Pharmaceuticals Inc (AUPH)

[Whalatane]

Z. To correct the previous post where I mentioned VERA .
Their LN P 3 trial has been suspended

This suspension follows a previous setback with atacicept in lupus nephritis - the Phase II/III APRIL-LN trial evaluating atacicept in addition to mycophenolate mofetil was prematurely terminated due to unexpected declines in serum IgG levels and occurrence of serious infections in patients receiving atacicept.
It's worth noting that atacicept has shown more promising results in other conditions like IgA nephropathy, where it demonstrated an acceptable safety profile and improvements in proteinuria in the Phase II JANUS study. However, its development for lupus nephritis has faced challenges, with the COMPASS trial being the latest setback. The lack of safety concerns as the reason for suspension suggests there may be other factors at play, but without more information, the exact cause remains unclear.

So VERA's LN program is no longer a threat to AUPH.

Kiwi